I’ve been following Altos Labs since its inception. The institution has intriguing, ambitious goals. For that reason, it’s been interesting that in terms of news on Altos, things have been relatively quiet for the last 4+ years. Some big changes have happened recently though. Altos Labs is high on talent, but nicely low-key on PR […]
Lately, we’ve been hearing more about something called “in vivo reprogramming.” It comes up frequently in the longevity space. Today’s post explains this cutting-edge area of research and its hoped-for, potential clinical applications. What’s most intriguing about vivo reprogramming is that it could potentially regenerate or heal tissues from the inside. It’s both exciting and
What is in vivo reprogramming, its potential pros & cons? Read More »
When I think of so-called aging supplements, visions of snake oil dance in my head. Possible benefits of supplements more generally have mostly not held up to long-term research. Supplements have risks too and so do purported longevity supplements. These pills claiming to fight aging are more in the realm of stem cell supplements that
Weekly reads: Altos Labs aging supplements pub, destructive NIH cuts, FDA warning, HSCs Read More »
At the beginning of the year I wrote about a new kind of biotech called Altos Labs. It’s very different in some ways from other institutions. I find it an intriguing research entity. Where do things stand now with Altos Labs a few months later? More information, new ideas, and questions have popped up in the
Altos Labs: mission, leadership, jobs, & CIRM Read More »
When we hear the word senile we might think stereotypically of an older person who has cognitive impairment, but some argue that senility can apply to cells too as they age and that such cells can be targeted by drugs called senolytics. Unfortunately, the supplements industry has picked up on this idea to sell iffy
Recommended reads: senolytics, cow iPS cells, big CIRM royalty Read More »